Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of multiple CSJ117 doses
(0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to
standard-of-care (SoC) asthma therapy in adult patients with uncontrolled asthma with respect
to change from baseline in FEV1 at the end of 12 weeks of treatment.